Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05003388 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 8, 2025 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites revised (2)v7
  2. Study sites: 3 to 2v6
  3. Start date: Feb 1, 2022 to Jun 26, 2021v5
  4. Study description expanded, about 30 wordsv4
  5. Study sites: 1 to 3
    • Start date changed from estimate of Feb 2022 to Feb 1, 2022
    v3
  6. Start date: Oct 2021 to Feb 2022
    • Site contact updated
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of multiple sclerosis
Trial Details
NCT Number NCT05003388
Lead Sponsor The Foundation for Orthopaedics and Regenerative Medicine
Conditions
(from sponsor)		 Multiple Sclerosis
Related terms Multiple Sclerosis
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov